Tolerability of Cefazolin After Immune-mediated Hypersensitivity Reactions to Nafcillin in the Outpatient Setting

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2014 Mar 19

PMID 24637693

Citations 9

Authors

Kimberly G Blumenthal

Ilan Youngster

Erica S Shenoy

Aleena Banerji

Sandra B Nelson

Affiliations

Soon will be listed here.

Abstract

The objective of the present study was to assess the safety and tolerability of cefazolin therapy among patients with methicillin-sensitive Gram-positive bacterial infections who develop non-IgE-mediated hypersensitivity reactions (HSRs) to nafcillin. In this retrospective cohort analysis of the Outpatient Parenteral Antimicrobial Therapy program at the Massachusetts General Hospital from 2007 through 2013, we identified patients switched from nafcillin to cefazolin after an immune-mediated HSR. We reviewed patient demographics, details about the original HSR, and outcomes after the switch to cefazolin therapy. HSRs were classified by reaction type and likely mechanism. There were 467 patients treated with nafcillin, of which 60 (12.8%) were switched to cefazolin during their prescribed course. Of the 60 patients who transitioned to cefazolin, 17 (28.3%) were switched because of non-IgE-mediated HSRs. HSRs included maculopapular rash (n = 10), immune-mediated nephritis (n = 3), isolated eosinophilia (n = 2), immune-mediated hepatitis (n = 1), and a serum sickness-like reaction (n = 1). All but one patient (94.1%) who switched to cefazolin tolerated the drug with resolution of the HSR and completed their therapy with cefazolin. No patient experienced worsening of their rash or progressive organ dysfunction. With appropriate monitoring, therapy with cefazolin after non-IgE-mediated HSRs to nafcillin appears to be safe.

Citing Articles

Management of Penicillin Allergy in the Perioperative Setting.

Sexton M, Kuruvilla M Antibiotics (Basel). 2024; 13(2).

PMID: 38391543 PMC: 10886174. DOI: 10.3390/antibiotics13020157.

Tolerability of Cefazolin in Nafcillin-Intolerant Patients for the Treatment of Methicillin-Susceptible Staphylococcus aureus Infections.

Gandhi A, Shah M, Donohue L, Cox H, Eby J Clin Infect Dis. 2021; 73(9):1650-1655.

PMID: 33905485 PMC: 8825210. DOI: 10.1093/cid/ciab368.

β-Lactam Allergy and Cross-Reactivity: A Clinician's Guide to Selecting an Alternative Antibiotic.

Caruso C, Valluzzi R, Colantuono S, Gaeta F, Romano A J Asthma Allergy. 2021; 14:31-46.

PMID: 33500632 PMC: 7822086. DOI: 10.2147/JAA.S242061.

Cephalosporin Allergy: Current Understanding and Future Challenges.

Khan D, Banerji A, Bernstein J, Bilgicer B, Blumenthal K, Castells M J Allergy Clin Immunol Pract. 2019; 7(7):2105-2114.

PMID: 31495420 PMC: 6955146. DOI: 10.1016/j.jaip.2019.06.001.

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Identified in the Electronic Health Record Allergy Module.

Wolfson A, Zhou L, Li Y, Phadke N, Chow O, Blumenthal K J Allergy Clin Immunol Pract. 2018; 7(2):633-640.

PMID: 30176295 PMC: 6363826. DOI: 10.1016/j.jaip.2018.08.013.

References

Nannini E, Stryjewski M, Singh K, Rude T, Corey G, Fowler Jr V . Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2010; 54(5):2206-8. PMC: 2863656. DOI: 10.1128/AAC.01325-09. View

Blanca M, Torres M, Garcia J, Romano A, Mayorga C, de Ramon E . Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics. J Allergy Clin Immunol. 1999; 103(5 Pt 1):918-24. DOI: 10.1016/s0091-6749(99)70439-2. View

Barbaud A . Skin testing in delayed reactions to drugs. Immunol Allergy Clin North Am. 2009; 29(3):517-35. DOI: 10.1016/j.iac.2009.04.010. View

Orbak Z, Sepetcigil O, Karakelleoglu C, Gulses S . Penicillin V-induced drug rash with eosinophilia and systemic symptoms. West Indian Med J. 2011; 59(6):722-5. View

. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010; 105(4):259-273. DOI: 10.1016/j.anai.2010.08.002. View

Chan K, Warren H, Thadhani R, Steele D, Hymes J, Maddux F . Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD. J Am Soc Nephrol. 2012; 23(9):1551-9. PMC: 3431413. DOI: 10.1681/ASN.2012010050. View

Chang F, Peacock Jr J, Musher D, Triplett P, MacDonald B, Mylotte J . Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore). 2003; 82(5):333-9. DOI: 10.1097/01.md.0000091184.93122.09. View

Romano A, Quaratino D, Di Fonso M, Papa G, Venuti A, Gasbarrini G . A diagnostic protocol for evaluating nonimmediate reactions to aminopenicillins. J Allergy Clin Immunol. 1999; 103(6):1186-90. DOI: 10.1016/s0091-6749(99)70197-1. View

Bouvresse S, Valeyrie-Allanore L, Ortonne N, Konstantinou M, Kardaun S, Bagot M . Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist?. Orphanet J Rare Dis. 2012; 7:72. PMC: 3517389. DOI: 10.1186/1750-1172-7-72. View

10.

Murphy E, Frick I . Gram-positive anaerobic cocci--commensals and opportunistic pathogens. FEMS Microbiol Rev. 2012; 37(4):520-53. DOI: 10.1111/1574-6976.12005. View

11.

Tally F, Gorbach S . Therapy of mixed anaerobic-aerobic infections. Lessons from studies of intra-abdominal sepsis. Am J Med. 1985; 78(6A):145-53. DOI: 10.1016/0002-9343(85)90118-4. View

12.

Schweizer M, Furuno J, Harris A, Johnson J, Shardell M, McGregor J . Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis. 2011; 11:279. PMC: 3206863. DOI: 10.1186/1471-2334-11-279. View

13.

Wynn M, Dalovisio J, Tice A, Jiang X . Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus. South Med J. 2005; 98(6):590-5. DOI: 10.1097/01.SMJ.0000145300.28736.BB. View

14.

Wolkenstein P, Chosidow O, Flechet M, Robbiola O, Paul M, Dume L . Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis. 1996; 35(4):234-6. DOI: 10.1111/j.1600-0536.1996.tb02364.x. View

15.

Hoppes T, Prikis M, Segal A . Four cases of nafcillin-associated acute interstitial nephritis in one institution. Nat Clin Pract Nephrol. 2007; 3(8):456-61. DOI: 10.1038/ncpneph0561. View

16.

E Pichichero M . Use of selected cephalosporins in penicillin-allergic patients: a paradigm shift. Diagn Microbiol Infect Dis. 2007; 57(3 Suppl):13S-18S. DOI: 10.1016/j.diagmicrobio.2006.12.004. View

17.

Bocquet H, Bagot M, Roujeau J . Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996; 15(4):250-7. DOI: 10.1016/s1085-5629(96)80038-1. View

18.

Cohen S, Klausner J, Engelman J, Philip S . Syphilis in the modern era: an update for physicians. Infect Dis Clin North Am. 2013; 27(4):705-22. DOI: 10.1016/j.idc.2013.08.005. View

19.

Bronnimann M, Yawalkar N . Histopathology of drug-induced exanthems: is there a role in diagnosis of drug allergy?. Curr Opin Allergy Clin Immunol. 2005; 5(4):317-21. DOI: 10.1097/01.all.0000173787.65777.77. View

20.

LaPlante K, Rybak M . Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2004; 48(12):4665-72. PMC: 529225. DOI: 10.1128/AAC.48.12.4665-4672.2004. View